The limits of sterility assurance by von Woedtke, Thomas & Kramer, Axel
The limits of sterility assurance
Die Grenzen der Sterilisationssicherheit
Abstract
Sterility means the absence of all viable microorganisms including vir-
uses. At present, a sterility assurance level (SAL) of 10
–6 is generally
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acceptedforpharmacopoeialsterilizationprocedures,i.e.,aprobability
of not more than one viable microorganism in an amount of one million
steriliseditemsofthefinalproduct.Byextrapolatingthereductionrates 1 INP Greifswald e.V. (Leibniz
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performance of the procedure of at least 12 lg increments (overkill
conditions) is demanded to verify an SAL of 10
–6. By comparison, other
recommendations for thermal sterilization procedures demand only 2 Institute for Hygiene and
Environmental Medicine, evidence that the difference between the initial contamination and the
University Greifswald,
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number of test organisms at the end of the process amount to more
than six orders of magnitude. However, a practical proof of the required
level of sterility assurance of 10
–6 is not possible. Moreover, the attain-
abilityofthisconditionisfundamentallydubious,atleastinnon-thermal
procedures.Thus,thequestionisdiscussedwhethertheundifferentiated
adherence to the concept of sterility assurance on the basis of a single
SALof10
–6correspondswiththesafetyrequirementsintermsofpatient
or user safety, costs and energy efficiency. Therefore, in terms of prac-
tical considerations, a concept of tiered SALs is recommended, analog-
ous to the comparable and well-established categorization into “High-
level disinfection”, “Intermediate-level disinfection” and “Low-level dis-
infection”. The determination of such tiered SALs is geared both to the
intended application of the sterilized goods, as well as to the character-
istics of the products and the corresponding treatment options.
In the case of aseptic preparation, filling and production procedures, a
mean contamination probability of 10
–3 is assumed. In automated pro-
cesses, lower contamination rates can be realized. In the case of the
production of re-usable medical devices, a reduction of at least 2 lg in-
crements can be achieved through prior cleaning in validated cleaning
and disinfecting devices. By chemical disinfection, a further reduction
of ≥5 lg increments is achieved. In the case of sterilized surgical instru-
ments, an additional concern is that they lay opened in contaminated
airforthedurationoftheoperation,atleastinconventionallyventilated
operatingtheaters.Finally,theamountofpathogensnecessarytocause
aninfectionmustbeconsidered.Bylogicalconsiderationofallaspects,
it seems possible to partially reduce sterility assurance levels without
any loss of safety. Proceeding from this, we would like to make the fol-
lowing suggestions for tiered SAL values, adjusted according to the re-
spective sterilization task:
• SAL 10
–6 for heat-resistant pharmaceutical preparations (parenter-
als), suggested term: “Pharmaceutical sterilization”,
• SAL 10
–4 for heat-resistant medical devices, suggested term: “High-
level sterilization”,
• SAL 10
–3 for heat-sensitive re-usable medical devices, under the
precondition of a validated cleaning efficacy of >4 lg increments,
suggested term: “Low-level sterilization”.
Keywords: sterility, sterility assurance level (SAL), draft of tiered SAL
values
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Research Article OPEN ACCESSZusammenfassung
Sterilität bedeutet die Abwesenheit aller vermehrungsfähigen Mikroor-
ganismen einschließlich Viren. Derzeit wird für Sterilisationsverfahren
einSterilitätssicherheits-Wert(SAL-Wert)von10
–6gefordert,d.h.ineiner
MengevoneinerMillionsterilisiertenGüterndarfhöchstenseinlebens-
fähiger Mikroorganismus zu erwarten sein. Durch Extrapolation der
Mikroorganismen-ReduktionsratennachartifiziellerextremerAusgangs-
kontamination (=10
6 Test-Mikrorganismen pro Prüfobjekt) wird zum
Nachweis eines SAL-Werts von 10
–6 eine theoretische Gesamtredukti-
onsleistung des Verfahrens um mindestens 12 lg-Stufen abgeleitet
(„Overkill“). Demgegenüber verlangen andere Empfehlungen lediglich
den Nachweis, dass die Differenz zwischen Ausgangszahl und Zahl der
TestorganismennachEndedesProzessesmehralssechsZehnerpoten-
zenbeträgt.DaderpraktischeNachweisdesgefordertenSterilisations-
sicherheitsniveaus von 10
–6 unmöglich ist und zumindest bei nichtther-
mischen Verfahren die Erreichbarkeit dieses Zustands grundsätzlich
zweifelhaftist,wirddieFragestellungdiskutiert,obeinundifferenziertes
Festhalten an dem gegenwärtigen praktizierten Konzept der Sterilisati-
onssicherheitaufderBasiseinesSAL-Wertesvon10
–6unterdemAspekt
der Patienten- bzw. Anwendersicherheit sowie der Kosten und des
Energieverbrauchs den tatsächlichen Sicherheitsanforderungen ent-
spricht.
Unter praktischen Gesichtspunkten wäre daher ein Konzept von abge-
stuftenSAL-WertenanalogderDifferenzierungin„High-level“,„Interme-
diate-level“bzw.„Low-leveldisinfection“sinnvoll,derenFestlegungsich
sowohl an der vorgesehenen Anwendung des Sterilisierguts als auch
an dessen Eigenschaften und den damit verbundenen Behandlungs-
möglichkeiten orientiert.
Bei aseptischen Zubereitungs-, Abfüllungs- und Herstellungsverfahren
wird von einer mittleren Kontaminationswahrscheinlichkeit von 10
–3
ausgegangen, bei automatisierten Prozessen können auch geringere
Kontaminationsratenrealisiertwerden.ImFallderAufbereitungwieder
verwendbarerMedizinprodukteistdurchdievorausgehendeReinigung
in Reinigungs-Desinfektions-Geräten eine Reduktion um mindestens
2lg-Stufenerreichbar.DurchdiechemischeDesinfektionwirdnachder
Reinigung eine weitere Reduktion um ≥5 lg-Stufen erreicht. Bei sterili-
siertemchirurgischemInstrumentariumkommthinzu,dassdasSterilgut
imkonventionellbelüftetenOperationssaalfürdieDauerderOperation
geöffnet auf dem Instrumentiertisch lagert. Schließlich muss auch die
Erregermenge berücksichtigt werden, die eine Infektion auszulösen
vermag.BeikonsequenterBerücksichtigungallerTeilaspekteerscheint
esmöglich,dieterminaleSterilisationsbehandlungohneSicherheitsver-
lustdeutlichzureduzieren.HierfürwirdeinVorschlagfürandiejeweilige
Sterilisationsaufgabe angepasste abgestufte SAL-Werte unterbreitet:
• SAL 10
–6 für thermostabile Arzneizubereitungen, vorgeschlagener
Terminus: „Pharmazeutische Sterilisation“,
• SAL 10
–4 für thermostabile Medizinprodukte, vorgeschlagener Ter-
minus: „High-level-Sterilisation“,
• SAL10
–3fürthermolabileMedizinprodukteunterderVoraussetzung
einervalidiertenReinigungseffektivität>4lg-Stufen,vorgeschlagener
Terminus: „Low-level-Sterilisation“.
Schlüsselwörter: Sterilität, Sterilitätssicherheits-Wert (SAL), Konzept
abgestufter SAL-Werte
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– a compromise between overkill,
viability and safety requirements
Sterility of a product or object means the complete ab-
senceofviablemicroorganisms,includingviruses,which
could pose a risk during administration [67], [81], [61],
[22]. A sterility assurance level (SAL) of 10
–6 is currently
required for sterilization procedures, i.e., a probability of
not more than one viable microorganism in one million
sterilized items of the final product [18].
The inherent problem with these requirements is that
evaluating the success of such sterilization by means of
a final inspection is all but impossible, since contamina-
tion rates on the order of an SAL of 10
–6 cannot be recor-
ded in experiments [59], [67], [46], [26].
Thus, model situations have to be created, with the help
of which conclusions can be drawn regarding the treat-
ment conditions necessary to attain sterility meeting the
SAL. Therefore, representative test organisms with a
maximum resistance to the procedure to be examined
are used for the purposes of auditing and qualifying
sterilization procedures. Consequently, the inactivation
of such highly resistant microorganisms encompasses
all less resistant organisms, including most pathogens.
Furthermore, the test organisms should be cultivable
under simple and most easily reproducible conditions. In
general, innocuous bacterial endospores fulfill these re-
quirements [41], [50], [31], [4]. In order to verify the ef-
ficacy of sterilization procedures, and to determine
treatment parameters, extremely large volumes of these
test organisms are used, typically ≥10
6 bacterial spores
per test object, e.g., in the form of bio-indicators [18].
When using the “Half-cycle method”, the action of half of
the intended sterilization cycle – usually half of the
treatment period – is examined. If, following this action,
acertainnumberofbio-indicatorscontaminatedwith10
6
resistant bacterial spores are inactivated, it can be con-
cluded that when applying the full cycle, an SAL of 10
–6
is guaranteed at a theoretical spore-inactivation rate of
≥12 lg increments. This corresponds to “Overkill condi-
tions” [37], [41], [30], [26].
However,inacourseofactionofthiskind,whichisbased
on the complete inactivation of a limited number of test
objects, it must be taken into account that there is a
statistical connection between the mean number of
contaminated test objects after treatment and the total
number of identically treated test objects. Accordingly,
themoretestobjectsareincludedinthetest,thegreater
the duration of treatment, concentration or dosage of
antimicrobially active agents must be to completely inac-
tivate a limited number of bio-indicators [66], [64], [87],
[65].
Incontrast,otherdirectionsandrecommendations–also
forheatsterilizationprocedures–onlydemandevidence
that the difference between the initial number of test
microorganismsandthenumberoftestorganismsatthe
end of the process amount to more than six orders of
magnitude, i.e., an inactivation rate ≥6 lg increments in
ordertoconsidertheSALof10
–6asattainedandindicate
the product treated in this way as sterile [14], [3].
What all methods used to prove the efficacy of steriliza-
tion procedures have in common is that the conditions
necessary to attain an extremely low probability of con-
tamination of 10
–6 are inferred from the treatment condi-
tions required to reduce extremely high artificial test
contaminations. This procedural method is based on the
general assumption of exponential inactivation kinetics
formicroorganismsundertheinfluenceofantimicrobially
effective parameters, from which a linear mortality curve
results, given a semi-logarithmic diagram.
There have been detailed trials and discussions, in par-
ticular concerning heat inactivation kinetics. As early as
1921, Bigelow put forward logarithmic inactivation kinet-
ics for microorganisms under the influence of heat. The
monograph by Konrich and Stutz [35], which was con-
sidered to be a standard work for many years, as well as
works by Machmerth [39], Pflug and Holcomb [48], Rus-
sell [51], Gould [23] and Knöller [34] provide detailed
analysesanddiscussionsoftherelevantliterature,includ-
ing experiments on this issue. The inactivation kinetics
for microorganisms initially postulated for heat treat-
ments,whichcorrespondedtofirst-orderreactionkinetics,
was also applied in principle to the conditions of the ac-
tionofionizingirradiationaswellaschemicalagentswith
antimicrobial effect [28], [83], [63], [42], [53].
Divergence from a strict semi-logarithmic course of the
mortality curve is usually explained by inhomogeneity of
thetestorganismpopulationsused.Theactualcomplexity
of microbiological inactivation kinetics cannot be clearly
andcomprehensivelydescribedusingsimplemathemat-
icalmodels,sothatthereisnouniformtheorywhichtakes
into account all possible courses of mortality curves for
the inactivation of microorganisms under the influence
ofnoxawithantimicrobialeffect[83].Consequently,while
in many cases the assumption of the linearity of inactiva-
tion kinetics in the semi-logarithmic standard simplifies
the actual circumstances, it offers the only practicable
possibilityforinterpretationandutilizationofdatagained
through experiments [39], [48], [37], [81], [34]. The cur-
rentEuropeanPharmacopoeiaalsoputsforwardtheview
that “the inactivation of microorganisms by physical or
chemical means follows an exponential law...” [18].
The fact that the objective of sterilization is to ensure a
rateofmicrobialcontaminationof≥10
–6survivingmicroor-
ganisms per test object results in the necessity of extra-
polatingmortalitycurvesfromtheareathatcanberecor-
ded in experiments to determine SAL-compatible steriliz-
ation parameters. As the description of the inactivation
kineticsbymeansofasimplemathematicalmodel,such
as first-order kinetics, already shows an approximation
within the area ascertainable in experiments, the associ-
ateduncertaintiesmustconsiderablyincreaseinthecase
of extrapolation outside this area [83]. Nevertheless,
procedural parameters intended to guarantee the attain-
ment of sterility that meets the SAL are usually defined
on the basis of extrapolation of this kind [41], [48], [4].
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for sterilization processes and the proof of a SAL ≤10
–6
asthequantitativeend-pointwhichhastobeguaranteed
by a sterilization process are not based on scientifically
provendata,butareonlyrulesofthumbandapproximate
values [34].
Conclusion: Using the SAL concept as a basis for the
evaluationoftheperformanceofsterilizationprocedures
constitutesasituation(whichisprobablyunique)inwhich
the certain attainment of a condition is required by law,
but there is no way of proving the attainment of this
condition in practical terms [22], [25], [24], [2]).
Concept for proving sterilization
assurance for heat-sensitive
medical devices
In our own tests to examine new concepts for the gentle
sterilization of irritable goods, applying non-thermal
physicaland/orchemicaltreatmentproceduresandusing
Bacillussubtilissporesastestorganisms,testconditions
were selected that, after treatment, either viable test or-
ganisms were still in evidence on the test objects or both
sterile and unsterile test objects were present simultan-
eously. By combining direct cell counting methods using
classicalmicroorganismrecoveryandcountingtechniques
[65], [48], [1] with the “fraction negative method” [64],
[65], [48], [62], mortality curves on the basis of experi-
mentaldataweremaintainedinarangeofabout8orders
of magnitude (≥10
6 to around 10
–2 test organisms per
test object). With reference to the known initial contam-
ination of the test objects, exact reduction factors could
be stated for the treatment parameters applied in each
case, to derive from these the treatment conditions ne-
cessary to attain sterility assurance in accordance with
the SAL [73], [74], [75].
Under this condition, the attainable degree of reduction
of the test organisms can be exactly quantified on the
one hand, and the actual inactivation kinetics can be
depicted on the other, at least in the range that can be
recorded using microbiological methods of proof. Addi-
tionally, possible inhomogenities of the mortality curves
can be taken into account for extrapolation into the SAL
area.
Conclusion:Exactquantitativestatementsastotheinac-
tivation kinetics and, accordingly, the antimicrobial effic-
acy can be made only if not all test objects are fully inac-
tivated,startingfromaknowninitialcontaminationfollow-
ing sub-effective treatment. Thus, for the quantitative
characterization of the efficacy of antimicrobial proced-
ures, the experimental conditions are to be chosen so
that in the result of treatment, surviving test organisms
are detectable for various individual treatments.
Variousexperimentsbythecurrentauthorsdemonstrated
thatinactivationkineticswithintheexperimentallyaccess-
iblerangebetween10
6and10
–2bacterialsporespertest
object never exhibited a linear course [33], [77], [76],
[74], [75]. In part, there were very pronounced concave
curves, consisting of an initial steep section which then
levelled off. At least with the non-thermal antimicrobially
active treatments examined, it was apparently possible
to reduce the high starting incidence in the test objects
to a low level using relatively short action duration, low
substance concentrations or low irradiation. However,
the efficacy against the residual contamination was con-
siderably lower. Consequently, an extrapolation of the
steepsectionoftherespectiveinactivationcurveintothe
SAL range of 10
–6 would result in treatment durations,
irradiation doses or substance concentrations which are
actuallymuchtoobrieftoguaranteeanadequatesterility
assurance. On the other hand, an extrapolation of the
second, flat part of the mortality curve would result in all
casesinextremesterilizationconditions,whichcouldnot
be applied practically.
Analogousmortalitycurvescanbefoundagainandagain
primarily in older publications. Seidl et al., for example,
reportedonexperimentsonradiosterilizationofmedicinal
products, in which it was possible to destroy 99.9% of a
test organism population with an irradiation dose of
0,1 Mrad (1 kGy); for the remaining 0.1%, however, a
dosage at least five times stronger was necessary [57].
PronouncedconcavemortalitycurvesforBacillussubtilis
spores dependent on varying gamma irradiation doses
canalsobefoundinWallhäußer[80].Pfeifferalsoreports
non-linear inactivation kinetics when applying ionizing ir-
radiation, because of disproportionate survival of radi-
ation-resistant microorganisms in the range of higher ir-
radiation doses [45], [47]. Furthermore, various works
on sporocidal efficacy of hydrogen peroxide show con-
cave, flattening-out mortality curves [72], [11], [5]. Van
Ooteghemdescribesnon-linearsurvivalcurvesformicroor-
ganisms under the influence of preservatives [71].
Such inactivation curves, also called “tailing” curves, are
explained predominantly (e.g., by Hermann [28] as well
as Wickramanayake and Sproul [83]) by the existence of
microorganismpopulationsonthetestobjectwithincon-
sistentresistancetotheantimicrobiallyactivetreatments
examined. Consequently, the less resistant fraction is
killedfirst(steepcurvesection);thepredominanceofthe
surviving, more resistant fraction then results in a flatter
course of the mortality curve. Spicher explains this phe-
nomenon in detail, coming to the conclusion that the
determinationoftheparametersofasterilizationproced-
uremustbeorientedtosuchextremevaluesrepresented
by highly resistant test organism fractions, since that re-
flects the actual circumstances [67].
The range between experimentally detectable contamin-
ation rates up to ca. 10
–2 test organisms per test object
and the SAL of 10
–6, still encompasses 4 lg increments,
whichcannotbeprovenbyexperimentaldata.Duetothe
inhomogeneityoftheinactivationkineticsalreadypresent
in the experimentally accessible range, it is not possible
to make any certain statement regarding the continuing
course of such mortality curves, which may increasingly
flatten out. Spicher already in 1993 expressly pointed
out that, in unfavorable cases, the highly resistant test
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curve, may no longer be determined using the usual mi-
crobiological testing procedures. As a result, the custom-
ary extrapolation of such curves into the SAL range in-
volves considerable risks [67].
Thus, it is clear that the general assumption of first-order
exponential inactivation kinetics, which was used origin-
ally to describe heat inactivation of bacteria, cannot be
applied without restrictions to non-thermal processes.
Oneapproachfortheinterpretationoftheseexperimental
results is the hypothesis that there is a basic difference
between thermal and non-thermal antimicrobial modes
of action, from which follows the assumption that such
non-linear mortality curves are not attributable solely to
the inhomogeneity of the test populations. Possibly, they
display a characteristic that can be generalized for all
inactivation procedures based on non-thermal actions
[77], [76]. From those treatment parameters that effect
elimination of the conventionally high test organism
numberspresentonbioindicatorsforsterilizationcontrol,
it is therefore not permissible – for sterilization proced-
ures in which efficacy relies on irradiation and/or chem-
icaleffects–todirectlyderivetreatmentconditionswhich
areintendedtoguaranteeareductionintotheexperiment-
ally no longer detectable but for sterilization assurance
essentialrange.Consequently,treatmentconditionsthat
ensureanSAL-compliantreductionuptoacontamination
rateofatleast10
–6cannotbeclearlydeterminedforsuch
procedures. The conclusion to be drawn from this is that
whennon-thermaltreatmentproceduresareapplied,the
condition of sterility that would conform with a contamin-
ation probability of 10
–6 cannot in fact be guaranteed.
Thus, the SAL concept is not a procedure suitable for
showing the efficacy of non-thermal sterilization pro-
cesses.
Consequently, only steam sterilization and sterilization
using dry heat should be described as sterilization pro-
cedures in the proper or traditional sense.
Sterility according to a SAL of 10
–6 should, logically, only
still be required for medical devices and preparations
that can be subjected to steam or hot air sterilization
using the required standard and equivalent procedures.
This is because it is possible that a homogeneous linear
mortality curve, and thus the sufficiently certain determ-
ination of the treatment conditions necessary to guaran-
tee an SAL of 10
–6, can be presumed only in thermal
procedures.
Other authors who carried out a detailed mathematical
analysis of the intrinsic uncertainties of the exponential
model of mortality of test organisms reach the same
conclusions in principle (while also taking into account
thermal inactivation kinetics). They explain that for dec-
ades,thisevidentlyinadequatetheoreticalbasishasbeen
adhered to without question, using the argument that,
due to extreme safety premiums, the safety of sterilized
products in practice is secured by assuming higher con-
tamination rates with extremely resistant test organisms
when examining sterilization procedures [8], [9].
In order to ensure the highest possible level of safety in
the application of non-thermal procedures, a proof of
“Antimicrobial efficacy on the highest experimentally ac-
cessible level” should be required.
This proof should show that the inactivation kinetics de-
pendent on the number of test organisms in the entire
range ascertainable in experiments can be evidenced
with performance data. As a rule, the performance char-
acterization for non-thermal antimicrobial procedures
should be carried out using test bodies contaminated
with low levels of highly resistant test organisms. This is
in order to reflect the fact that, apparently in contrast to
the relatively simple option of reducing high numbers,
the inactivation of low levels of residual contamination
is disproportionately more difficult to achieve. Test mi-
croorganisms with a high level of resistance to the pro-
ceduretobeexaminedshouldbeusedastestorganisms,
e.g., bacterial spores. It must be proven that a reduction
of the number of test organisms by at least five lg incre-
ments up to a contamination rate of 10
–2, which can only
just be proven in experiments, has been achieved. In
general, only the strict concentration on data that can be
recorded in experiments affords the possibility of being
able to directly compare various procedures and proced-
ural steps using inactivation kinetics and, consequently,
to make available differing, but equivalent inactivation
procedures for various products. The extrapolation of
such inactivation kinetics recorded in experiments by
merely one additional lg increment to a contamination
level of 10
–3 would guarantee a sufficient "Safety premi-
um” for the determination of the necessary treatment
parameters. Here, a “tiered” SAL of 10
–3 could be intro-
ducedfornon-thermalsterilizationprocedures.Thisvalue
is also referred to repeatedly in the literature on this
subject [22], [24], [86].
In order to differentiate it from actual sterilization with
an SAL of 10
–6, which should be restricted to thermal
procedures,suchagentlesterilizationproceduretargeted
at a contamination probability of 10
–3 could be called
”Low-level sterilization”. The efficacy of ”Low-level steril-
ization” concentrates primarily on the range of low levels
of residual contamination with highly resistant microor-
ganisms on goods to be sterilized, following effective
preparation (aseptic processing and/or cleaning and
subsequent disinfection), which is very important in
practice.
Do the current theoretical sterility
assurancerequirementsreflectthe
actual safety requirements?
Itwasascertainedthatthepracticalproofoftherequired
level of sterility assurance of 10
–6 is not possible.
Moreover,theattainabilityofthisconditionisfundament-
ally questionable, at least in non-thermal procedures.
Furthermore, it is questionable whether the undifferenti-
ated adherence to the currently practiced concept of
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–6complies
with the actual safety requirements in terms of patient
or user safety [2]. The practical relevance of an SAL of
10
–6 is not conclusively proven, i.e., it is practically im-
possibletofindadifferenceintherateofinfectionresult-
ing from the application of products that were sterilized
with a (theoretical) SAL of 10
–6 on the one hand, or on
the other hand were treated using a procedure in which
only a contamination likelihood of 10
–3 is ensured [85].
By extrapolating the reduction rates following extreme
artificial initial contamination to an SAL of 10
–6, a theor-
eticaloverallperformanceoftheprocedurecanbeestab-
lished by at least 12 lg increments (overkill conditions).
SuchanSAL,however,isneitherevidencebasednorcan
it be accurately ascertained in experiments, or attained
practically.
Furthermore, it must be taken into consideration that, by
adhering to an SAL of 10
–6 as a “gold standard” for steril-
ization, unnecessarily high costs are incurred, the intro-
ductionofnewsterilizationproceduresismadeconsider-
ably more difficult [2], and no allowance is made for the
requirement of sustainable development.
Therefore, for practical reasons, a concept of tiered SALs
wouldmakesense,theestablishmentofwhichisoriented
towards the intended application of the sterilized goods,
thecharacteristicsofsuchgoods,andthecorresponding
treatmentoptions.Indisinfectionprocedures,ananalog-
ous categorization of “High-level disinfection”, “Interme-
diate-leveldisinfection”,and“Low-leveldisinfection”,has
been customary for some time already [69], [10], [52],
[55], [60].
Since the mid-1990s, there have been repeated sugges-
tionsforthedefinitionoftieredsterilityassurancevalues,
suchasa“ConceptoftieredSALs”,thesuggestionofthe
declaration of “Asepsis assurance values” [22], [86], or
a declaration as “Aseptic: Safe for its designated use”,
which is oriented more towards the intended application
of the product [24], [2].
The determination of the respective safety level should
be oriented towards both the features and the quality of
the products (e.g., new products being used for the first
time and single-use products, as opposed to re-usable
and re-processed goods etc.), as well as the intended
application.
In practice, in the course of modern quality-controlled
production and preparation procedures for pharmaceut-
icalsandmedicaldevices,onlyaverylowlevelofcontam-
ination is to be expected. In the case of aseptic prepara-
tion, filling and production procedures, a contamination
probabilityof10
–3isassumed;lowercontaminationrates
can also be realized in automated processes [18], [45],
[41], [85], [81], [17], [24], [13], [44]. For the use of
gamma radiation for sterilization, possibilities of determ-
ining dosage by ascertaining the number, type and radi-
ation resistance of microbiological contaminants on the
goods to be sterilized have been discussed and applied
in practice for several years [45], [49], [27], [47].
The possible inclusion of the real contamination risk for
the products to be sterilized in the course of the quality
control of production processes could become general
practice to determine the necessary sterilization treat-
ment conditions and the resulting level of safety. This
would also correspond to the suggested concentration
of the proof of efficacy of a sterilization procedure on the
low level of residual contamination with more highly res-
istant microorganisms.
In addition to the degree of contamination prior to steril-
ization,theperiodbetweensterilizationandintendeduse
aswellastheriskofrecontaminationand/orproliferation
of microorganisms during the storage period must also
betakenintoaccount.Thus,e.g.,foraqueousparenterals,
it is by all means reasonable to demand an SAL of 10
–6.
Inthecaseoftheproductionofre-usablemedicaldevices,
a reduction of at least 2 lg increments can be achieved
throughpriorcleaninginvalidatedcleaninganddisinfect-
ing devices (CDD). In CDDs for containers for human
egesta, the reduction rate was 3 to >5 lg increments,
depending on the procedure [82]. Due to the require-
ments for chemical disinfection, a further reduction by
≥5 lg increments is achieved through disinfection follow-
ing cleansing in the reprocessing procedure [21]. This
means that because of the preceding reprocessing pro-
cedure for medical devices, at least 7 lg increments are
usually added to the actual sterilization performance.
Based on a consistent consideration of the reduction
performance of all partial steps of reprocessing and
sterilizationprocedures,itwouldbepossibletomarkedly
reducethefinalsterilizationtreatmentwithoutareduction
in safety. The prerequisite for this is the validation of all
partial process steps, which is required in any case.
In the case of sterilized operating instruments, an addi-
tionalfactormustbetakenintoaccountintheriskassess-
ment. In conventionally ventilated operating theaters,
sterile goods are removed from their sterile packaging in
the theater and are stored opened on the instrument
table for the duration of the operation. During this time,
they are exposed to the risk of contamination from sedi-
mentation of airborne or particle-borne pathogens, re-
leased mainly by the operating team. Even in the case of
low-turbulence displacement flow (LDF) and subject to
the premise that the sterile goods are opened within the
LDF and the table of instruments is also situated com-
pletely within the LDF, according to DIN 1946-2 and -4,
up to 10 CFU/m
3 (CFU – colony forming units) may be
contained in the airflow following the filter emissions of
the ventilation equipment (around 10 cm apart) in an
empty, unused, and previously cleaned and disinfected
operating theater [15], [16]. The pathogens released by
the operating team, which cannot be fully removed by
the LDF, are added to this. Thus, the overkill sterilization
safety level currently required is disproportionately high
compared to the actual probability of contamination of
the operating instruments following sterilization [58].
The infection dose must also be taken into account as a
further factor in the risk assessment. With the exception
of a possible divergent infectivity specific to a certain
strain, one can assume that, as a rule, fewer than 10
5
bacteriaper1goftissuearenotsufficientforthecreation
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fectivity, however, even small numbers of bacteria
(10
3–10
4)canpotentiallycauseinfections.Otheraspects,
such as the location of the infection, intensity of the
wound infection, irritation caused by foreign bodies, cir-
culation,andimmunityalsoinfluencetherateofinfection.
Thus, in the presence of suturing material, just 10
2 sta-
phylococci per gram of tissue can be sufficient to cause
a wound infection [20], [56], [25], [2]. However, even in
the most unfavorable case of an infection dose ≥10
1 (for
which there is no evidence), this as a rule refers to one
species, e.g., S. aureus. Since an initial contamination of
operating instruments with >10
9 of the same species is
more than unlikely (1 g of excrement contains up to 10
11
bacteria per gram in relation to the total number, but not
to one species [6]) and at least 10
7 lg increments are
eliminated by the reprocessing procedure preceding
sterilization;eventheinactivationof6lgincrementsonly
in thermal procedures includes a sufficient security
premium for all contamination eventualities.
Based on these considerations, we would like to make
the following suggestions for discussion of tiered SAL
values adjusted to correspond to the respective steriliza-
tion task [78]:
• SAL 10
–6 for heat-resistant pharmaceutical prepara-
tions, suggested term: “Pharmaceutical sterilization”
• SAL10
–4forheat-resistantmedicaldevices,suggested
term: “High-level sterilization”
• SAL 10
–3 for heat-sensitive re-usable medical devices
on the condition of prior validated cleaning efficacy
>4lgincrements,suggestedterm:“Low-levelsteriliza-
tion”
• Proof of antimicrobial efficacy on the highest experi-
mentally accessible level for all other products which,
according to understanding to date, are to be applied
sterile, suggested term: “Microbiologically safe for the
designated use”
In addition to product damage, which is well known and
which has been examined above all in connection with
radiation sterilization [43], [32], [40], [84], more recent
tests show that the interaction between antimicrobial
treatment processes and the material characteristics or
the functional features of the products treated obviously
has to be assessed in a considerably more differentiated
fashion than was previously believed in the case of
sensitive goods that are to be sterilized [12], [36], [74],
[79]. Consequently, even if the microbiological validation
of gentle sterilization procedures is optimized, its use
especiallyforsensitivegoodswithspecialareasofapplic-
ation may continue to be subject to considerable and
possibly even more stringent restrictions. Ultimately, the
extent to which an increase in the intensity of the effect
of an antimicrobial noxa actually offers such an increase
in microbiological safety that the possible consequences
for the functionality and/or bio-compatibility can be justi-
fied, must be analyzed in detail in each individual case.
Duetothemultitudeofinteractionsbetweenantimicrobi-
allyeffectivecomponentsinaprocedureandtheproducts
treated, a conclusive decision about the suitable antimi-
crobial treatment for very specific goods can be made
only following a specific risk assessment.
Thus, the sterilization procedure in each individual case
of application must be optimized anew.
Generally,theresultofthisisthatuniformanduniversally
applicable recommendations for gentle sterilization,
above all of thermolabile products, cannot be made.
Because sterility is currently demanded for products
sensitive to the established sterilization methods, the
use of tiered SAL values can avoid the situation in which
thisdemandpracticallycannotevenbemetattheoutset,
and, consequently, these products must currently be im-
plemented on an assurance level that is inadequately
microbiologically defined in terms of its ability to prevent
infection.
This sophisticated concept of sterility assurance levels
would also result in the entitlement for both bacteria-re-
tentive filtration and aseptic preparation to be classified
as methods of preparation of sterile products. Although
this is the case in the current version of the European
Pharmacopoeia[19],todatethishasbeenneithertheor-
etically nor practically validated.
Furthermore, the introduction of tiered SAL levels could
also make the introduction of alternative sterilization
methods considerably easier.
In general, in order to guarantee a high level of microbio-
logical safety, the entire production or preparation pro-
cess, but above all the steps preceding the actual steril-
ization treatment, would have to be taken into account
morethantheyhavebeenuptonowtoensurethemicro-
biologicalsafetyofthefinalproduct.Thisapproach,which
buildsonconceptsalreadyintroducedinthe1980s[39],
[38], [29], takes into account the effects attainable on
all levels within an overall outcome to ensure the micro-
biological quality of a final product. With regard to the
growingepidemiologicalimportanceofvirusesandespe-
cially prions, which are extremely difficult to inactivate,
thisistheonlywaytoensuresufficientlevelsofinfection-
prevention safety [54], [70], [68].
In the future, it will be imperative that aspects of steriliz-
ation or sterilizability are taken into account as early as
possibleinthedesignofbothproductsandtheproduction
and application processes involving these products, so
that ultimately, an optimized strategy is adjusted to each
specific product to ensure the highest possible level of
infection-preventionsafety.Thiswillenablethemanufac-
turer and the user “to build sterility into a product as op-
posed to building a product and testing it for
sterility” [41].
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